Document is current

Article History

Accepted: 8 November 2024

First Online: 28 November 2024

Declarations

:

: No external funding was used in the preparation of this manuscript.

: H.Y. reports a relationship with Organization for Clinical Medicine Promotion that includes consulting or advisory. Y.I. reports a relationship with Daiichi Sankyo Inc that includes employment. A.S. reports a relationship with Kyowa Kirin Co Ltd that includes consulting or advisory, funding grants, and speaking and lecture fees. A.S. reports a relationship with Asahi Kasei Pharma Corporation that includes speaking and lecture fees. A.S. reports a relationship with Takeda Pharmaceutical Company Limited that includes consulting or advisory, funding grants, and speaking and lecture fees. A.S. reports a relationship with Shionogi Pharma Co Ltd that includes consulting or advisory. A.S. reports a relationship with Mallinckrodt Pharmaceuticals that includes consulting or advisory. A.S. reports a relationship with Daiichi Sankyo Inc that includes funding grants and speaking and lecture fees. A.S. reports a relationship with Chugai Pharmaceutical Co Ltd that includes funding grants and speaking and lecture fees. A.S. reports a relationship with Eisai Co Ltd that includes speaking and lecture fees. A.S. reports a relationship with Janssen Pharmaceuticals Inc that includes speaking and lecture fees. A.S. reports a relationship with Kissei Pharmaceutical Co Ltd that includes speaking and lecture fees. A.S. reports a relationship with Merck Biopharma that includes speaking and lecture fees. A.S. reports a relationship with Merck & Co Inc that includes speaking and lecture fees. A.S. reports a relationship with Mitsubishi Tanabe Pharma Corporation that includes speaking and lecture fees. A.S. reports a relationship with Nipro Corporation that includes speaking and lecture fees. A.S. reports a relationship with Novo Nordisk Pharma Co Ltd that includes speaking and lecture fees. A.S. reports a relationship with Ono Pharmaceutical Co Ltd that includes speaking and lecture fees. A.S. reports a relationship with Pfizer Inc that includes speaking and lecture fees. A.S. reports a relationship with Sanofi KK that includes speaking and lecture fees. A.S. reports a relationship with Nippon Kayaku Co Ltd that includes speaking and lecture fees. A.S. reports a relationship with JCR Pharmaceuticals Co Ltd that includes speaking and lecture fees. Y.S. and M.M. declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

: This study was conducted in accordance with the Declaration of Helsinki and Good Pharmacoepidemiology Practices. Per the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects, ethical review and informed consent were not required, as this was a noninterventional, retrospective study that used anonymized patient data.

: Not applicable.

: Not applicable.

: The claims database used for this study can only be obtained by purchasing from a vendor (Medical Data Vision Co., Ltd; ).

: Conceptualization: Y.S., M.M., H.Y., and A.S. Data curation: Y.S., M.M., and Y.I. Formal analysis: Y.S. and Y.I. Funding acquisition: A.S. Investigation: Y.S. Methodology: Y.S. and A.S. Project administration: A.S. Resources: A.S. Software: Y.S. and Y.I. Supervision: H.Y. and A.S. Validation: Y.S. and Y.I. Visualization: Y.S. Writing—original draft: Y.S., M.M., and H.Y. Writing—review and editing: M.M., H.Y., Y.I., and A.S.